Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Down 35.4% in June

Medicus Pharma Ltd (NASDAQ:MDCX – Get Free Report) was the target of a large decline in short interest in June. As of June 15th, there was short interest totaling 1,928,591 shares, a decline of 35.4% from the May 31st total of 2,984,551 shares. Based on an average daily volume of 1,878,019 shares, the days-to-cover ratio is currently 1.0 days. Currently, 3.7% of the shares of the stock are short sold.

Medicus Pharma Stock Performance

Medicus Pharma stock opened at $0.40 on Thursday. Medicus Pharma has a 52 week low of $0.25 and a 52 week high of $3.69. The firm has a market capitalization of $22.66 million, a price-to-earnings ratio of -0.15 and a beta of -0.06. The company has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.80.

Get Medicus Pharma alerts:

Medicus Pharma (NASDAQ:MDCX – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.13). Equities analysts forecast that Medicus Pharma will post -0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Private Advisor Group LLC boosted its position in Medicus Pharma by 3.8% during the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after acquiring an additional 5,500 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares during the period. Jane Street Group LLC acquired a new position in shares of Medicus Pharma in the 2nd quarter valued at about $41,000. Commonwealth Equity Services LLC lifted its position in shares of Medicus Pharma by 161.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after purchasing an additional 17,611 shares in the last quarter. Finally, May Hill Capital LLC lifted its position in shares of Medicus Pharma by 100.0% in the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock worth $55,000 after purchasing an additional 17,811 shares in the last quarter.

Analyst Ratings Changes

Several analysts recently commented on MDCX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research note on Friday, April 10th. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Medicus Pharma in a research report on Monday, April 20th. Finally, Roth Mkm began coverage on Medicus Pharma in a report on Tuesday, April 21st. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Check Out Our Latest Research Report on Medicus Pharma

Medicus Pharma Company Profile

(Get Free Report)

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.

Featured Articles

• Five stocks we like better than Medicus Pharma
• Tesla Stock Surges 15% as FSD Update Backs Its Autonomy Thesis
• Is the Memory Rally Still Alive After the Semiconductor Sell-Off?
• AirJoule Unveils Prime System, Clearing Path to Commercialization
• Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks

Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.